GILD
Gilead Sciences Inc
NASDAQ: GILD · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$125.59
-0.22% today
Updated 2026-06-12
Market cap
$158.39B
P/E ratio
17.36
P/S ratio
5.33x
EPS (TTM)
$7.35
Dividend yield
2.43%
52W range
$102 – $156
Volume
6.4M
Gilead Sciences Inc (GILD) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed GILD price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$125.59
Today
Analyst consensus
$156.93
+24.95% · 12M
2030 Base
$105.40
-16.08% future
NPV today
$79.53
@ 6% WACC
29 analysts:
25 Buy4 Hold0 Sell
Management guidance
Gilead raised FY2026 revenue guidance to $31.05B (5.46% growth from $29.44B in 2025), implying normalized run-rate of ~$31-32B. Management emphasized HIV franchise strength (Lenacapavir momentum, priority review status for bictegravir/lenacapavir combo), oncology expansion (Arcellx CAR-T, Tubulis ADC platform acquisition for $5B), and autoimmune pipeline (Ouro Medicines $2.2B acquisition). No explicit 2027-2030 guidance provided; however, pipeline commentary and $10B+ in M&A commitments signal confidence in mid-to-high single-digit topline growth supported by HIV market share gains and oncology/inflammation scale-up.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
GILD · Gilead Sciences Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$40.31
NPV today: $30.42
Base case (2030)
$105.40
NPV today: $79.53
Bull case (2030)
$170.49
NPV today: $128.64
WallStSmart.com
GILD financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $29.4B | $31.1B | $33.5B | $36.3B | $38.8B | $41.2B |
| Revenue growth | 2.4% | 5.5% | 8.0% | 8.1% | 6.9% | 6.3% |
| Net margin | — | 34.2% | 40.1% | 45.8% | 48.8% | 51.6% |
| EPS | $8.11 | $8.50 | $10.75 | $13.20 | $15.00 | $16.80 |
| Diluted shares | — | 1248M | 1253M | 1258M | 1263M | 1267M |
| Net debt | — | $18.97B | $12.52B | $5.54B | $-1.92B | $-9.84B |
| P/S multiple | — | 3.0x | 3.0x | 3.0x | 3.0x | 3.0x |
| Implied price (base) | — | $59.45 | $70.35 | $82.11 | $93.67 | $105.40 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $41.2B | $41.2B | $41.2B |
| P/S multiple | 1.0x | 3.0x | 5.0x |
| Diluted shares | 1267M | 1267M | 1267M |
| Net debt | $-9.84B | $-9.84B | $-9.84B |
| Implied P/E † | 2x | 6x | 10x |
| 2030 Price | $40.31 | $105.40 | $170.49 |
| NPV @ 6% | $30.42 | $79.53 | $128.64 |
† Implied P/E: Multiples remain elevated across all three scenarios because GILD is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $105.40 base case
GILD catalysts and risks
Growth catalysts
+ Lenacapavir for HIV prevention: PEPFAR/Global Fund expanded investment, priority review for bictegravir/lenacapavir combo (FDA approval potential 2026-2027), international launch expansion in endemic regions
+ Oncology platform maturation: Arcellx anito-cel CAR-T commercial ramp (first launches 2026), Tubulis ADC platform integration driving next-gen oncology pipeline (potential launches 2027-2028)
+ Autoimmune/inflammation: Ouro Medicines TCE assets advancing in Phase 2 (immune reset positioning), addressing high-TAM inflammatory disease market
+ Cell & Gene therapy: Arcellx integration positions Gilead as cell therapy leader; synergies with oncology/inflammation programs
+ Viral hepatitis: New data presentations at EASL 2026; potential for HCV/HBV mono/combo approvals supporting legacy franchise stabilization
+ Strategic M&A execution: $10B+ committed to bolt-on acquisitions; demonstrated management execution risk/reward
Key risks
- HIV market competition: MSD (Idvynso once-daily combo), other integrase/capsid combos could fragment market share; Lenacapavir access limitations in developed markets due to pricing/uptake barriers
- Oncology commercialization risk: Arcellx anito-cel ramp dependent on manufacturing scale, payer adoption, and CAR-T market maturation; Tubulis ADC platform is clinical-stage with execution risk
- Viral hepatitis revenue erosion: HCV/HBV franchise mature with declining prevalence; pipeline renewal critical but uncertain
- Acquisition integration: Arcellx ($7.8B), Tubulis ($5B), Ouro ($2.2B) integration execution risk; IPR&D charges depressing near-term EPS despite strong revenue
- Margin pressure: R&D and acquisition-related costs expected to remain elevated through 2027-2028; gross margins stable but operating margin compression likely
- Regulatory/reimbursement: HIV pricing pressure in US/EU; oncology/autoimmune reimbursement risk in key markets; GLP-1 competition for obesity indications if Gilead explores that space
Methodology · Gilead Sciences Inc 2030 stock forecast model
Gilead Sciences Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 29 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (2% cumulative for GILD by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-9.84B by 2030) |
| 3. Time value | NPV calculated using 6% WACC (CAPM: beta 0.332) |
| 4. Multiple framework | P/S compresses with scale: bear 1.0x / base 3.0x / bull 5.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
GILD price target FAQ
What is the GILD price target for 2030?
WallStSmart's Gilead Sciences Inc 2030 base case is $105.40 per share, with a bull case of $170.49 and bear case of $40.31. The NPV of the base case discounted to today at 6% WACC is $79.53.
How is the Gilead Sciences Inc 2030 stock forecast calculated?
The GILD 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the GILD price target account for dilution?
Gilead Sciences Inc is projected to grow diluted share count from 1242M to 1267M by 2030 (a 2% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 2%.
What is the analyst consensus on GILD stock?
29 analysts cover GILD with an average 12-month price target of $156.93. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.